Finance

Peptide drugs-focused biopharma company reports strong third quarter results

Published in Biotech Business Week, December 26th, 2005

Unigene Laboratories, Inc. (UGNE) reported financial results for the period ended September 30, 2005 with revenue for the quarter of $11,873,000 compared to $5,216,000 for the same 3 months in 2004.

Revenue for the 9 months ended September 30, 2005 was $12,676,000 compared to $6,409,000 for the 9 months in 2004.

Revenue for both the 3-month and 9-month periods ended September 30, 2005 included Fortical product sales to Upsher-Smith Laboratories (USL) representing launch quantities into distribution channels as well as royalties earned from USL sales following the August 16 product launch.

UGNE's net income for the 9 months ended...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry